Dr Shivani Misra is a clinical associate professor and honorary consultant in diabetes at Imperial College London ...
Quintuple agonists herald a new era in obesity care, unlocking the potential for powerful, sustained weight loss and improved ...
HELLO! explores Mounjaro side effects and what to expect when you come off the drug, based on the latest clinical guidance ...
Mounjaro shows promise for young patients with Type 2 diabetes and obesity. A recent study reveals its active ingredient, ...
Zacks.com on MSN
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
Eli Lilly's diversified pipeline, rapid tirzepatide growth and rising estimates give it the edge over Novo Nordisk in the ...
A new Penn Nursing study suggests that the weight-loss drug tirzepatide may cause fewer side effects like nausea and vomiting ...
When you factor in those hurdles, it’s fair to wonder how close we are to GLP-1 pills. Turns out, there is already a GLP-1 pill on the market—it just doesn’t have the same weight loss impact as ...
Learn how tirzepatide treatment improves diet-related quality of life and satisfaction in Type 2 diabetes patients.
Viking Therapeutics targets obesity and MASH with high-risk prospects, trial concerns, and strong funding, but lags leaders ...
Novo Nordisk's Q2 2025 sales surge as Wegovy demand grows, driven by new obesity drug data. Click here to read an analysis of ...
Ozempic, marketed by Novo Nordisk in India, is primarily indicated for the treatment of type 2 diabetes. While it can lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback